Symbols

OABI

OmniAb·NASDAQ

--(--)

OABI fundamentals

OABI Q4 2025 Earnings

OmniAb (OABI) released its earnings on Mar 4, 2026: revenue was 8.38M (YoY -22.47%), missed estimates; EPS was -0.11 (YoY +8.33%), missed estimates.

Revenue / YoY

8.38M

-22.47%

EPS / YoY

-0.11

+8.33%

Report date

Mar 4, 2026

OABI Earnings Call Summary for Q4,2025

Partnership growth: 107 partners running 407 active programs, +44 net programs YoY.
Tech innovation: Launched OmniUltra (ultra-long CDRH3) and Exploration (high-throughput B-cell screening) in Q4 2025.
Financial trajectory: 2026 revenue guidance of $25-30M, operating expenses of $80-85M, targeting cash flow breakeven.
Clinical momentum: 25 program advancement events in 2025, including 1 registration-stage program.
New revenue streams: Exploration deployed 2 instruments in 2025, OmniUltra generating early partner interest.

Earnings

EPS

Revenue

Revenue & Expenses

OABI has released its 2025 Q4 earnings report, with revenue of 8.38M, reflecting a YoY change of -22.47%, and net profit of -14.18M, showing a YoY change of -8.50%. The Sankey diagram below clearly presents OABI's revenue sources and cost distribution.

Key Indicators

OmniAb (OABI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

OmniAb (OABI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

OmniAb (OABI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

OmniAb (OABI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown